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Previous studies have shown that immunological factors are involved in the pathogen-
esis of autism spectrum disorders (ASDs). However, this research has been conducted 
almost exclusively in Western contexts, and only a handful of studies on immune 
measures have been conducted in Asian populations, such as Chinese populations. 
The present study examined whether immunological abnormalities are associated with 
cognitive deficits and problem behaviors in Chinese children with ASD and whether 
these children show different immunological profiles. Thirteen typically developing (TD) 
children and 22 children with ASD, aged 6–17 years, participated voluntarily in the study. 
Executive functions and short-term memory were measured using neuropsychological 
tests, and behavioral measures were assessed using parent ratings. The children were 
also assessed on immunological measures, specifically, the levels of cytokines and 
chemokines in the blood serum. Children with ASD showed greater deficits in cognitive 
functions, as well as altered levels of immunological measures, including CCL2, CCL5, 
and CXCL9 levels, compared to TD children, and the cognitive functions and associ-
ated behavioral deficits of children with ASD were significantly associated with different 
immunological measures. The children were further sub-classified into ASD with only 
autistic features (ASD-only) or ASD comorbid with attention deficit hyperactivity disorder 
(ASD + ADHD). The comorbidity results showed that there were no differences between 
the two groups of ASD children in any of the cognitive or behavioral measures. However, 
the results pertaining to immunological measures showed that the children with ASD-
only and ASD +  ADHD exhibited distinct cytokine and chemokine profiles and that 
abnormal immunologic function was associated with cognitive functions and inattention/
hyperactivity symptoms. These results support the notion that altered immune functions 
may play a role in the selective cognitive and behavioral symptoms of ASD.
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inTrODUcTiOn
One essential finding in autism spectrum disorder (ASD) research 
has been the consistent immunological abnormality detected 
among autistic individuals. Although it is largely unknown how 
the immunologic factor specifically affects the neural networks 
in the brains of individuals with ASD, dysfunctional immune 
profiles involving inflammatory changes in the CNS have been 
documented in ASD. For example, increased levels of inflamma-
tory cytokine transforming growth factor beta 1 [TGFβ1; (1)], 
chemokine macrophage chemoattractant CCL2 (1), and CXCL8 
(2) were found in the brains of individuals with ASD. In addition 
to the elevated neuroinflammatory response in the autistic brain, 
altered levels of circulating cytokines and chemokine have also 
been reported. For example, higher levels of macrophage migra-
tion inhibitory factor (MIF) and CXCL8 were observed in plasma 
and cerebrospinal fluid (CSF) specimens from individuals with 
ASD compared with those from typically developing (TD) con-
trols and subjects with other developmental disabilities (1, 3–5). 
In addition, elevated plasma CCL5 and CCL2 were observed 
in ASD, whereas increased CCL2 found newborn bloodspot 
specimens have been shown to be related to the risk of ASD (1, 
6, 7). Similarly, altered levels of TGFβ1 have also been found in 
plasma and serum specimens of ASD compared with TD controls 
(8–10). These findings suggest that the increased inflammatory 
chemokine and cytokine production detected in the brain and 
peripheral blood of autistic individuals may produce a profoundly 
negative effect on proper neuronal development, migration, dif-
ferentiation, and synapse formation and subsequently affect the 
behavior of individuals with ASD (1, 11, 12). Consistent with these 
findings, cytokine and chemokine levels have been shown to cor-
relate with the severity of behavioral abnormalities in individuals 
with ASD. Increased plasma levels of MIF have been correlated 
with more severe social impairment and decreased imaginative 
play (4), whereas lower TGFβ1 levels have been associated with 
more stereotypy, irritability, hyperactivity, and other behavioral 
symptoms and fewer adaptive behaviors (8). Significant associa-
tions between increased plasma levels of CCL5 and CXCL8 and 
more frequent aberrant behaviors and fewer adaptive behaviors 
have also been found (3, 6).
Although the aforementioned studies have indicated plausible 
links between the severity of certain core behavioral symptoms 
and shifts in cytokine and chemokine levels in ASD, it is important 
to note that the exploration of neuroinflammatory mechanisms 
in ASD has been based predominantly on research conducted 
in Western populations, of which the expression of autistic traits 
does not necessarily extend to all populations. For example, ASD 
children from Western populations (United Kingdom and United 
States) showed significantly greater deficits in the domains of non-
verbal communication/socialization and insistence on sameness/
restricted interests than ASD children from Eastern populations 
(Israel and South Korea), as was demonstrated in a study con-
ducted by Matson et al. (13). Therefore, it may be worth consider-
ing whether the immunological profiles in ASD differ according to 
ethnicity. Moreover, it will be interesting to determine whether the 
observed ethnic differences in the symptoms of ASD are reflected 
in their immunological profiles such that ethnic differences are 
also observed in the levels of cytokine and chemokine production 
among autistic individuals from different ethnic backgrounds. 
Hence, our present study attempted to add new knowledge 
regarding the ethnic aspects of immunological dysfunctions in 
the peripheral blood of Chinese individuals with ASD.
Furthermore, although the relationship between the levels of 
cytokine and chemokine production and the severity of cogni-
tive outcomes have been detected in ASD (3, 4, 6, 8), reports of 
peripheral chemokine levels have been inconsistent. For example, 
while higher levels of CCL2, CCL5, and CXCL10 were found in 
individuals with ASD than in TD controls in either plasma or CSF 
specimens (1, 6, 7), lower plasma levels of these three chemokines 
were detected in ASD subjects with fragile X syndrome (FXS, a 
single-gene disorder characterized by autistic symptoms) com-
pared to TD controls (14). Similarly, several studies have reported 
decreased levels of TGFβ1 measured in plasma and serum (8–10), 
whereas the opposite trend has been observed in the brain tissue 
of individuals with ASD (1). Considering the discrepancies in the 
levels of cytokine and chemokine production reported in previous 
studies, it is questionable whether this relationship arises simply 
because chemokine and cytokine levels vary between different 
samples or because of the complexity of the clinical diagnosis of 
ASD, in which autism may be comorbid with symptoms associ-
ated with other neurological disorders, leading to the expression 
of different immunological profiles. Indeed, differing levels of 
chemokines were found between individuals with ASD + FXS and 
individuals with ASD-only, as well as between autistic individuals 
with regression and those with early onset of ASD (3, 14). Because 
there is a significant proportion of individuals with ASD comor-
bid with AD/HD symptoms (ASD + ADHD) who demonstrate 
a more severe profile of cognitive and behavioral impairment 
compared to individuals with only autistic features, this study also 
aimed to explore whether individuals with ASD and individuals 
with ASD + ADHD demonstrate different immunological profiles 
in terms of cytokine and chemokine production levels (15–19).
The purpose of the present study was therefore to (a) explore 
whether the patterns of the serum cytokine levels and chemokine 
production observed in individuals with ASD from Western 
populations would be replicated in ASD children from Eastern 
populations and (b) investigate whether the immunological 
measures of ASD would be associated with the severity of their 
behavioral and cognitive symptoms. To further highlight the 
relationship between altered immune functions and the diversity 
of autistic phenotypes, this study also aimed to (c) determine 
whether individuals diagnosed with ASD and co-diagnosed 
with ASD and ADHD would demonstrate different cytokine and 
chemokine profiles compared to their age- and IQ-matched TD 
counterparts. Drawing together the pieces of evidence linking 
ASD with altered immunologic function, we hypothesized that 
relative to TD children, Chinese children with ASD would show 
altered levels of inflammatory chemokine and cytokine in the 
blood serum. In addition, given that altered pro-inflammatory 
profile might be associated with neuronal damage which leads 
to the behavioral abnormalities in individuals with ASD, it 
was hypothesized that the specific panels of pro-inflammatory 
cytokines and chemokines would be associated with the sever-
ity of the cognitive dysfunction and behavioral problems in the 
TaBle 1 | Demographic and clinical characteristics of children with asD 
(n = 22) and TD controls (n = 13).
TD asD t or χ2 p
(n = 13) (n = 22)
Age, years 10.92 (3.95) 9.50 (2.54) 1.17 0.26
Gender—male (%)a 69.23 90.91 2.62 0.11
IQ 106.69 (13.23) 99.36 (8.29) 1.80 0.09
ADI-R social interaction 3.85 (2.91) 18.55 (6.77) 8.89 <0.001**
ADI-R communication 1.31 (1.38) 13.64 (5.27) 10.39 <0.001**
ADI-R stereotyped behavior 0.23 (0.60) 5.18 (2.24) 9.80 <0.001**
SRS-2 total score 28.77 (10.29) 78.55 (25.94) 8.00 <0.001**
Data are presented as means (SD).
ADI-R, Autism Diagnostic Interview-Revised; IQ, intelligence quotient as assessed by 
the Chinese version of Wechsler Intelligence Scale for Children Forth Edition; SRS-2, 
Social Responsiveness Scale Second Edition; ASD, children with diagnosis of autism 
spectrum disorder; ASD-only, children with diagnosis of autism spectrum disorder 
only; ASD + ADHD, children with comorbid diagnosis of autism spectrum disorder and 
attention deficit hyperactivity disorder; TD, typically developing children.
aLikelihood ratio Chi-square test were performed for distribution violating the sample 
size assumption of Chi-square test.
**p < 0.01.
TaBle 2 | Demographic and clinical characteristics of children with asD only (n = 13), children with comorbid diagnosis of asDs and attention deficit 
hyperactivity disorder (n = 9), and TD controls (n = 13).
TD asD F or χ2 p Post hoc results
(n = 13)
asD-only (n = 13) asD + aDhD (n = 9)
Age, years 10.92 (3.95) 9.38 (2.84) 9.67 (2.18) 0.84 0.44
Gender—male (%)a 69.23 100.00 77.78 6.49 0.04*
IQ 106.69 (13.23) 100.08 (9.30) 98.33 (6.98) 2.06 0.14
ADI-R social interactionb 3.85 (2.91) 19.31 (7.18) 17.44 (6.37) 37.20 <0.001** TD < ASD-only, ASD + ADHD
ADI-R communicationb 1.31 (1.38) 13.77 (4.90) 13.44 (6.06) 51.42 <0.001** TD < ASD-only, ASD + ADHD
ADI-R stereotyped behaviorb 0.23 (0.60) 5.85 (2.19) 4.22 (2.05) 50.51 <0.001** TD < ASD-only, ASD + ADHD
SRS-2 total scoreb 28.77 (10.29) 81.08 (28.68) 74.89 (22.51) 30.56 <0.001** TD < ASD-only, ASD + ADHD
Data are presented as means (SD).
ADI-R, Autism Diagnostic Interview-Revised; IQ, intelligence quotient as assessed by the Chinese version of Wechsler Intelligence Scale for children Forth Edition; SRS-2, Social 
Responsiveness Scale Second Edition; ASD, children with diagnosis of autism spectrum disorder; ASD-only, children with diagnosis of autism spectrum disorder only; ASD + ADHD, 
children with comorbid diagnosis of autism spectrum disorder and attention deficit hyperactivity disorder; TD, typically developing children.
aLikelihood ratio Chi-square test were performed for distribution violating the sample size assumption of Chi-square test.
bWelch’s test and Games–Howell post hoc test were performed for variables violating the homogeneity of variances assumption of ANOVA test.
*p < 0.05, **p < 0.01.
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children with the disorder. Finally, considering the discrepancies 
in the levels of cytokine and chemokine production reported in 
previous studies, it was further hypothesized that the children 
with ASD would have a different cytokine and chemokine profile 
from those comorbid with ADHD.
MaTerials anD MeThODs
Participants
Participants in the study were recruited by posting advertisement 
on our websites and sending emails to parents in our existing 
database at the Neuropsychology Laboratory of the Chinese 
University of Hong Kong. Seventeen TD children and 23 children 
with ASD, aged 6–17 years, participated voluntarily in the study 
with their parents’ written consent. All children with ASD were 
diagnosed by a clinical psychologist based on the diagnostic 
criteria of DSM-V (20), and the information collected from the 
Autism Diagnostic Interview-Revised [ADI-R; (21)]. Of the 23 
children with ASD, 10 children also demonstrated prominent 
symptoms of attention deficit hyperactivity disorder (ADHD) 
that warranted a comorbid diagnosis of ASD and ADHD 
(ASD + ADHD) and 13 met the diagnostic criteria of ASD with 
no or only mild ADHD-like features that did not meet the diag-
nostic criteria of ADHD (ASD-only). The TD children had no 
history of delay in developmental milestones or any neurological 
or psychiatric disorders as reported by their parents; the children 
were screened for autism traits using the ADI-R and the Social 
Responsiveness Scale [SRS-2; (22)]. One ASD +  ADHD child 
who was prescribed immunosuppressive drugs was excluded 
from the study, and four children from the TD group were also 
excluded because their scores were either above the cutoff scores 
of 10, 9, and 3 in the three subscales (reciprocal social interaction, 
communication, repetitive/restricted and stereotyped patterns of 
behaviors, respectively) of the ADI-R (n = 3), or of the total raw 
score of 70 in the SRS-2 (n = 1).
Tables 1 and 2 shows the demographic and clinical charac-
teristics of the children. The ASD and TD groups were matched 
on age, t = 1.17, p = 0.26, and intellectual functioning, t = 1.80, 
p = 0.09, as measured by the short form of the Chinese version 
of the Wechsler Intelligence Scale for Children-Fourth Edition 
(Hong Kong) [WISC-IV (HK)] (23). The ASD-only group 
contained significantly more males than the other two groups, 
likelihood ratio = 6.49, p = 0.04. The TD group demonstrated 
significantly fewer ASD or ADHD related symptoms than 
either ASD group (F ranges from 30.56 to 51.42, p <  0.001). 
Although the level of behavioral problems between the two 
ASD groups did not reach statistical significance, the ASD-only 
group demonstrated slightly more ASD-related features than the 
ASD + ADHD group.
Procedure
This study was conducted in accordance with the Helsinki 
Declaration of the World Medical Association Assembly. 
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The research protocol was approved by the Joint Chinese 
University of Hong Kong—New Territories East Cluster 
Clinical Research Ethics Committee (Ref. No. 2013.520). Prior 
to the assessment, all of the children and their parents were 
briefed on the procedure of the study, and informed consent 
was obtained from the parents. Peripheral blood samples and 
data on neuropsychological and behavioral measures were 
collected on separate days.
A registered nurse drew 3 ml of EDTA blood and 3 ml of clot-
ted blood from each child using venipuncture at a medical clinic. 
Each blood sample was centrifuged at 3,000 rpm for 15 min, and 
the harvested serum was then stored at −80°C in a clinical labora-
tory until cytokine and chemokine levels were measured. Serum 
cytokine and chemokine concentrations were measured follow-
ing the manufacturer’s instructions. Blood sample processing and 
assay were performed by an experienced laboratory technician 
who was blind to the clinical characteristics and group assign-
ments of the participants.
Neuropsychological assessments of the children and clinical 
interviews of the parents were administered on another day 
by well-trained research assistants. The neuropsychological 
assessment involved standardized tests on two cognitive 
domains (executive functioning and short-term memory) that 
are frequently found to be problematic in individuals with ASD 
(24, 25). In the clinical interview, information about the chil-
dren’s developmental and medical history, as well as past and 
present socio-emotional and behavioral characteristics, was 
collected from the parents through a structured interview and 
standardized questionnaires. The diagnosis of each child was 
confirmed by a clinical psychologist based on the DSM-V cri-
teria and the ADI-R. The research assistants who conducted the 
assessment, the nurse who drew the blood, and the technician 
who performed the blood assays were blinded to the rationale 
of the study and the group assignment.
Measures
Immunological Measures
The concentrations of the cytokines TGFβ1 and MIF were 
measured using an enzyme-linked immunosorbent assay 
(R&D Systems, Inc., MN, USA) method, whereas those of the 
chemokines CCL2, CCL5, CXCL8, CXCL9, and CXCL10 were 
assessed using BD™ human chemokine cytometric bead array 
(CBA) reagent (Becton Dickinson Biosciences Pharmingen, 
CA, USA). Samples were analyzed on a multi-fluorescence BD 
FACSCalibur™ flow cytometer using BD CellQuest™ and BD™ 
CBA software.
Cognitive Measures
Executive Functioning
Four well-defined measures of executive functioning in planning 
and organization, cognitive flexibility, and generativity were 
used in the present study: (1) the Tower of London Test-Drexel 
Version (TOLDX) (26), (2) completion time of the second trial 
of the Children’s Color Trail Test [CCTT; (27)], (3) the total 
number of unique designs of the Five Point Test [FPT; (28)], and 
(4) the Copy trial of the Rey–Osterrieth Complex Figure Test 
[Rey-O; (29)]. The TOLDX requires movement of three colored 
beads on three vertical pegs to match a target arrangement while 
adhering to the test rules. The second trial of the CCTT requires 
connecting scattered numbers in ascending order and concur-
rently alternating between pink and yellow. The FPT requires 
the production of novel designs by connecting five points with 
straight lines within 5 min. The Rey-O Copy task involves copy-
ing a complex geometric figure and requires sufficient attention 
and concentration and the ability to organize the figure into a 
perceptual whole.
Short-term Memory
Short-term memory comprises two measures tapping the ability 
to temporarily store new information in memory: (1) total scores 
on Digit Span—Forward and Backward (DS) of the WISC-IV 
(HK) (23) and (2) the immediate recall trial of Rey-O. The Rey-O 
task requires drawing a complex figure from memory after copy-
ing the figure, and the DS requires the repetition of sequences of 
random numerals read aloud by the examiner.
Behavioral Measures
Social Communication/Interaction
This measure consists of three measures derived from two stand-
ardized questionnaires tapping core deficits in social functioning 
of ASD: (1) reciprocal social interaction, (2) communication 
subscale scores of the ADI-R, and (3) social communication/
interaction total scores on the Social Responsiveness Scale, 
Second Edition [SRS-2; (22)].
Repetitive/Restricted Behavior
This measure consists of two behavioral measures tapping another 
set of core ASD symptoms in the repetitive, restricted behavior 
repertoire, interests or activities: (1) restricted, repetitive, and ste-
reotyped patterns of behaviors subscale scores on the ADI-R and 
(2) repetitive/restricted behaviors subscale scores on the SRS-2.
Inattention/Hyperactivity
This measure involves three measures derived from standardized 
questionnaires tapping core AD/HD symptoms of inattention and 
hyperactivity/impulsivity: (1) cognitive problems/inattention, (2) 
hyperactivity, and (3) ADHD index subscale scores on the short 
version of Conners’ Rating Scales-Revised [CRS-R; (30)].
Data analyses
Cognitive functions and behavioral measures were compared 
and examined for differences between the ASD and TD groups. 
To reduce the number of statistical comparisons, two composite 
scores of the cognitive domain (executive functioning, short-term 
memory) and three composite scores of the behavioral domain 
(social communication/interaction, repetitive/restricted behavior, 
inattention/hyperactivity) were computed by summing and 
averaging the Z scores from the corresponding cognitive and 
behavioral measures of the different cognitive and behavioral 
domains. Low scores indicated poor performance in cognitive 
functioning and impaired behavior. To examine differences 
TaBle 3 | comparison of mean composite scores in cognitive and 
behavioral domains in children with asD (n = 22) and TD controls 
(n = 13).
TD asD t p
(n = 13) (n = 22)
Executive functioning −0.30 (0.50) −0.71 (0.60) 2.09 0.04*
Short-term memory −0.08 (0.70) −0.74 (0.62) 2.90 0.007**
Social communication/
interaction
3.10 (0.37) −0.19 (1.20) 11.93 <0.001**
Repetitive/restricted 
behavior
1.53 (0.21) −0.88 (1.07) 10.23 <0.001**
Inattention/hyperactivity 0.22 (0.51) −1.48 (1.14) 6.01 <0.001**
Data are presented as means (SD).
ASD, children with diagnosis of autism spectrum disorder; ASD-only, children with 
diagnosis of autism spectrum disorder only; ASD + ADHD, children with comorbid 
diagnosis of autism spectrum disorder and attention deficit hyperactivity disorder; TD, 
typically developing children.
*p < 0.05, **p < 0.01.
TaBle 4 | comparison of mean concentrations of cytokines and 
chemokines in children with asD (n = 22) and TD controls (n = 13).
TD asD t p
(n = 13) (n = 22)
cytokines
Migration inhibitory 
factor (ng/mL)
17.25 (5.35) 20.89 (11.30) −1.09 0.29
Transforming growth 
factor beta 1 (pg/mL)
31530.81 
(5746.58)
32228.70 
(8917.55)
−0.25 0.80
chemokines
CCL2 (pg/mL) 141.78 (38.89) 182.21 (66.61) −2.27 0.03*
CCL5 (pg/mL) 32396.60 
(8061.28)
45273.38 
(16620.41)
−3.07 0.004**
CXCL8 (pg/mL) 79.87 (18.20) 78.83 (33.00) 0.12 0.91
CXCL9 (pg/mL) 522.64 (212.87) 270.19 (100.92) 4.02 0.001**
CXCL10 (pg/mL) 1155.78 (493.21) 999.70 (415.49) 1.00 0.32
Data are presented as means (SD).
ASD, children with diagnosis of autism spectrum disorder; TD, typically developing 
children.
*p < 0.05, **p < 0.01.
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between the ASD and TD groups of children, the two cogni-
tive composite and the three behavioral composite scores were 
compared using the independent-samples t-test (independent 
t-test). For the immunological measures, the concentrations of 
the cytokines and chemokines were compared between the ASD 
and TD groups using independent t-tests.
To determine whether ASD and ASD + ADHD would dem-
onstrate different cytokine and chemokine profiles compared 
to their TD counterparts, between-group comparisons on 
continuous variables were performed using multivariate analysis 
of variance (MANOVA) followed by separate univariate analysis 
of variance (ANOVA) and post hoc Tukey HSD tests. Between-
group comparisons on categorical variables were analyzed using 
Chi-square tests. For distributions that had more than 20% of 
cells with an expected count of less than 5, the likelihood ratio 
was reported. Spearman’s correlation was performed to analyze 
the association between two continuous variables. All statistical 
analyses were performed using the SPSS software (SPSS, Inc., 
Chicago, IL, USA). Given that specific hypotheses were tested, 
the alpha level was not adjusted to avoid reducing the power of 
the tests, and the corresponding effect sizes of different statistics 
were reported to determine the strength of association and 
degree of difference based on Cohen (31) and Hopkins (32) 
criteria.
resUlTs
comparison of cognitive and Behavioral 
Measurements between children with 
asD and TD controls
Children with ASD showed significantly lower composite scores in 
all cognitive domains: executive functioning, t(33) = 2.09, p = 0.04, 
and short-term memory, t(33) = 2.90, p = 0.007; and in all behav-
ioral domains: social communication/interaction, t(33) = 11.93, 
p < 0.001, repetitive/restricted behavior, t(33) = 10.23, p < 0.001, 
and inattention/hyperactivity, t(33) = 6.01, p < 0.001, compared 
to TD controls, indicating deficient cognitive and behavioral 
functioning in ASD (Table 3).
comparison of immunological Profiles 
between children with asD and TD 
controls
Concentrations of CCL2 and CCL5 were significantly higher in 
children with ASD than in those with TD [CCL2: t(33) = −2.27, 
p = 0.03; CCL5: t(33) = −3.07, p = 0.004] (Table 4). Moreover, 
concentration of CXCL9 was approximately twofold lower in 
ASD children than in TD children, t(33) = 4.02, p = 0.001. No 
significant differences in the concentrations of MIF, TGFβ1, 
CXCL8, and CXCL10 were observed in children with ASD com-
pared with those observed for TD children, p > 0.05. The results 
were consistent when only male participants in each group were 
compared. That is, significant between-group differences were 
found in CCL2, t(27) = −1.93, p = 0.03, CCL5, t(27) = −2.28, 
p =  0.03, and CXCL9, t(27) =  3.69, p =  0.02, suggesting that 
a gender difference was not a confounding factor that could 
account for differences in the immunological measures between 
the ASD and TD groups of children. Similarly, analysis of covari-
ance was conducted to examine whether the differences between 
the TD and ASD groups could be attributed to age differences. 
Similar patterns of statistical significance were observed between 
the two groups after age adjustments were made, in which the 
level of CCL5 was significantly higher, F(1, 32) = 5.33, p = 0.03, 
and the CXCL9 level was significantly lower, F(1, 32) =  23.09, 
p <  0.001, in children with ASD than their TD counterparts. 
Nevertheless, although the level of CCL2 showed a higher trend 
in the ASD group after an adjustment was made for age, the dif-
ference between the ASD and TD groups did not reach statistical 
significance, F(1, 32) = 3.23, p = 0.08.
associations between concentrations of 
cytokines and chemokines with cognitive 
and Behavioral Measures in the asD and 
TD groups
Spearman’s rank-correlation analysis was performed to deter-
mine whether there were correlations between concentrations 
TaBle 5 | Whole-group association analysis of serum cytokines and chemokines with cognitive and behavioral domains in all participants enrolled in 
this study (n = 35) using spearman’s rank correlations.
Migration 
inhibitory factor
Transforming 
growth factor beta 1
ccl2 ccl5 cXcl8 cXcl9 cXcl10
rs p rs p rs p rs p rs p rs p rs p
Executive functioning −0.48 0.003** 0.01 0.97 0.24 0.16 −0.16 0.36 0.10 0.58 0.26 0.13 0.49 0.003**
Short-term memory −0.30 0.08 −0.10 0.56 −0.10 0.55 −0.19 0.27 −0.06 0.72 0.07 0.70 0.10 0.58
Social communication/
interaction
−0.20 0.25 0.04 0.83 −0.12 0.51 −0.39 0.02* −0.04 0.84 0.49 0.003** 0.19 0.27
Repetitive/restricted 
behavior
−0.10 0.55 0.00 0.99 −0.09 0.62 −0.39 0.02* 0.03 0.88 0.49 0.003** 0.18 0.30
Inattention/hyperactivity −0.19 0.26 −0.17 0.32 −0.19 0.26 −0.70 <0.001** −0.07 0.69 0.30 0.08 0.08 0.67
*p < 0.05, **p < 0.01.
TaBle 6 | asD subgroup association analysis of serum cytokines and chemokines with cognitive and behavioral domains in participants with asD 
(n = 22) using spearman’s rank correlations.
Migration inhibitory 
factor
Transforming growth 
factor beta 1
ccl2 ccl5 cXcl8 cXcl9 cXcl10
rs p rs p rs p rs p rs p rs p rs p
Executive functioning −0.57 0.005** 0.06 0.79 0.39 0.07 −0.14 0.53 0.26 0.24 −0.06 0.80 0.63 0.002**
Short-term memory −0.28 0.21 −0.03 0.88 −0.15 0.51 −0.04 0.84 −0.03 0.88 −0.59 0.004** −0.04 0.85
Social communication/
interaction
−0.10 0.65 0.32 0.15 0.13 0.58 −0.13 0.58 −0.02 0.92 −0.05 0.83 0.28 0.20
Repetitive/restricted 
behavior
0.12 0.60 0.23 0.31 0.17 0.46 −0.05 0.82 0.16 0.47 −0.22 0.34 0.03 0.89
Inattention/hyperactivity −0.37 0.09 −0.17 0.44 −0.16 0.49 −0.62 0.002** −0.05 0.82 −0.36 0.10 −0.12 0.59
*p < 0.05, **p < 0.01.
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of cytokines and chemokines and the cognitive and behavioral 
domains among ASD and TD participants. To reduce the number 
of statistical comparisons and thereby avoid inflation of Type I 
error, composite Z scores were computed for each of the two 
cognitive (executive functioning and short-term memory) and 
three behavioral (social communication/interaction, repetitive/
restricted behavior and inattention/hyperactivity) domains. First, 
individual Z scores for each cognitive or behavioral measure were 
computed based on the mean and SD obtained from normative 
sample statistics. The composite Z score of each cognitive and 
behavioral domain was then calculated by taking the average of 
the individual Z scores for the cognitive or behavioral measures 
tapping the corresponding domain.
Table 5 shows the specific associations between concentra-
tions of cytokines and chemokines with cognitive and behav-
ioral domains assessed among all participants. Generally, fewer 
significant associations were observed between concentrations 
of chemokines and the cognitive domains than between those 
concentrations and the behavioral domains. For the cogni-
tive domains, significant associations were found between 
MIF, CXCL10, and EF scores, such that lower EF scores were 
significantly correlated with increased concentrations of MIF, 
r = −0.48, p = 0.003, and reduced concentrations of CXCL10, 
r =  0.49, p =  0.003. For the behavioral domains, significant 
associations were found between increased CCL5 and lower 
composite scores in all of the behavioral domains, namely 
social communication/interaction, r = −0.39, p = 0.02, repeti-
tive/restricted behavior, r = −0.39, p = 0.02, and inattention/
hyperactivity, r = −0.70, p < 0.001. Similarly, associations were 
also found between decreased concentrations of CXCL9 and 
poorer performance in all of the behavioral domains: social 
communication/interaction, r  =  0.49, p  =  0.003, repetitive/
restricted behavior, r = 0.49, p = 0.003, except that a non-signif-
icant trend of association could only be detected in inattention/
hyperactivity, r =  0.30, p =  0.08. Most of these associations 
between concentrations of cytokines and chemokines and the 
cognitive and behavioral domains showed moderate to large 
effect sizes, and the strongest association was found between 
increased CCL5 and lower composite scores for inattention/
hyperactivity.
associations between concentrations of 
cytokines and chemokines with cognitive 
and Behavioral Measures within 
the asD group
To determine whether there was specific relationship between 
measures of cytokines and chemokines and severity of cognitive 
and behavioral outcomes among children with ASD, a second cor-
relation analysis was performed within the ASD group (as shown 
in Table 6). When the ASD group was analyzed alone, lower EF 
scores were found to be significantly correlated with increased 
TaBle 7 | comparison of mean composite scores in cognitive and behavioral domains between children with asD only (n = 13), children with comorbid 
diagnosis of asDs and attention deficit hyperactivity disorder (n = 9), and TD controls (n = 13).
TD asD F or α2 p Post hoc results
(n = 13)
asD-only (n = 13) asD + aDhD (n = 9)
Executive functioning −0.30 (0.50) −0.50 (0.59) −1.02 (0.50) 5.06 0.01* TD < ASD + ADHD
Short-term memory −0.08 (0.70) −0.61(0.67) −0.94 (0.50) 4.96 0.01* TD < ASD + ADHD
Social communication/interactiona 3.10 (0.37) −0.29 (1.24) −0.05 (1.21) 65.85 <0.001** TD < ASD, ASD + ADHD
Repetitive/restricted behaviora 1.53 (0.21) −1.08 (1.13) −0.59 (0.97) 50.34 <0.001** TD < ASD, ASD + ADHD
Inattention/hyperactivitya 0.22 (0.51) −1.28 (1.20) −1.75 (1.04) 18.89 <0.001** TD < ASD, ASD + ADHD
Data are presented as means (SD).
ASD, children with diagnosis of autism spectrum disorder; ASD-only, children with diagnosis of autism spectrum disorder only; ASD + ADHD, children with comorbid diagnosis of 
autism spectrum disorder and attention deficit hyperactivity disorder; TD, typically developing children.
aWelch’s test and Games–Howell post hoc test were performed for variables violating the homogeneity of variances assumption of analysis of variance test.
*p < 0.05, **p < 0.01.
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MIF, r = −0.57, p =  0.005, and decreased CXCL10, r =  0.63, 
p = 0.002. In addition, we found a significant correlation between 
concentration of CXCL9 and STM scores, such that as CXCL9 
increased, STM performance decreased, r = −0.59, p =  0.004. 
Regarding the behavioral domains, the only association observed 
was that between the concentration of CCL5 and composite scores 
of inattention/hyperactivity at a large effect size, such that as the 
concentration of CCL5 increased, more inattention and hyperac-
tive symptoms occurred, r = −0.62, p = 0.002. However, no other 
association was observed between the composite scores of social 
communication/interaction, repetitive/restricted behavior and 
concentrations of cytokines and chemokines.
comparison of cognitive and Behavioral 
Measurements between children with 
asD-Only and children with asD + aDhD
To examine the associated deficits and immunological profiles 
in ASDs comorbid with other disorders, the children with ASD 
in the present study were further divided into two groups: those 
who were diagnosed with ASD-only and those with a comorbid 
diagnosis of ASD and ADHD (ASD +  ADHD). As shown in 
Table  7, no significant differences in any of the cognitive and 
behavioral domains were observed between children with 
ASD-only and those with ASD + ADHD. However, differences 
between the two ASD groups in the EF score were observed such 
that children with ASD + ADHD tended to perform poorer than 
children with ASD-only in the EF domain, p =  0.07. Children 
with ASD +  ADHD also tended to show lower performance 
in the STM domain and had more features in the inattention/
hyperactivity domain than did children with ASD-only. However, 
no significant between-group difference was detected, possibly 
because of the relatively small sample size in each of the ASD 
subgroups.
comparison of immunological Profiles 
among children with asD-Only and Those 
with asD + aDhD
Two separate MANOVA tests were performed to compare, first, 
the concentrations of cytokines and, second, the concentrations 
of chemokines among ASD-only, ASD  +  ADHD and TD 
controls, followed by post  hoc Tukey HSD tests to examine 
the pair-wise group differences in concentrations of cytokines 
and chemokines. Figure  1 shows the mean concentrations of 
cytokines and chemokines in each group. Results of MANOVA 
showed that there were significant between-group differences 
in both the profiles of cytokines, F(4, 62) =  2.90, p =  0.03, 
ηp
2 0 16= . , and the profiles of chemokines, F(10, 56)  =  3.66, 
p =  0.001, ηp2 0 40= . . Moreover, separate univariate ANOVAs 
on the dependent variables revealed that there were signifi-
cant group differences in one cytokine [MIF: F(2, 32) =  4.35, 
p  =  0.02, ηp2 0 21= . ], and four chemokines [CCL2: F(2, 
32) = 4.32, p = 0.02, ηp2 0 21= . ; CCL5: F(2, 32) = 3.40, p = 0.05, 
ηp
2 0 18= . ; CXCL8: F(2, 32)  =  4.52, p  =  0.02, ηp2 0 22= . ; 
CXCL9: F(2, 32) =  11.52, p <  0.001, ηp2 0 42= . ]. In contrast, 
there were no significant group differences with respect to the 
concentrations of TGFβ1, F(2, 32) = 0.23, p = 0.80, ηp2 0 01= . , or 
CXCL10, F(2, 32) = 0.80, p = 0.46, ηp2 0 05= . . Since the ASD-
only group contained significantly more males than the TD and 
the ASD + ADHD groups, MANOVA tests were performed to 
examine whether there was gender difference in the cytokine 
and chemokine expressions within the ASD + ADHD and TD 
groups of children. Results showed that there was no significant 
gender difference in the profiles of cytokines or chemokines in 
the ASD + ADHD or TD groups, ps > 0.30. Moreover, results 
of separate univariate ANOVAs on the dependent variables also 
revealed that there was no significant group difference in any of 
the immunological measures between the males and females in 
the ASD + ADHD and TD groups, ps > 0.05. The results suggest 
that the females in the ASD + ADHD and TD groups exhibit 
similar cytokine and chemokine profiles as compared to their 
male counterparts and that the sex difference is not a confound-
ing factor in the immunological measures between these groups.
Deviated Concentrations of Cytokines and 
Chemokines in ASD-Only Children
Regarding the deviated concentrations of cytokines and 
chemokines in ASD-only children, post  hoc Tukey HSD tests 
showed that ASD-only children demonstrated significantly higher 
CCL2 concentrations, p = 0.02, and lower CXCL9 concentrations, 
FigUre 1 | comparisons of mean concentrations of cytokines and chemokines between the asD-only, asD+aDhD, and TD groups. The error bars 
represent a 95% confidence interval around the mean. TD, typically developing children; ASD-only, children with diagnosis of autism spectrum disorder; ASD + ADHD, 
children with comorbid diagnosis of ASD and attention deficit hyperactivity disorder (ADHD). *p < 0.05, **p < 0.01.
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p < 0.001, than did the TD controls. In contrast, there were no 
significant differences between the ASD-only children and TD 
controls in the concentrations of two cytokines (MIF: p = 0.99; 
TGFβ1: p = 0.87) or three other chemokines (CCL5: p = 0.10; 
CXCL8: p = 0.43; CXCL10: p = 0.86) (Figure 1).
Deviated Concentrations of Cytokines and 
Chemokines in ASD Children Comorbid with ADHD
Post hoc Tukey HSD test results showed that ASD +  ADHD 
children demonstrated a dissimilar immunological profile com-
pared with that of ASD-only children (Figure 1). With respect to 
cytokine concentration, the ASD + ADHD group demonstrated 
a significantly higher MIF concentration than did the TD group, 
p = 0.04, but no such deviated concentration was observed for 
the ASD-only group. With respect to chemokine concentra-
tion, a significantly elevated CCL2 pattern was observed for 
the ASD-only group, p  =  0.02, whereas no significant eleva-
tion of CCL2 concentrations was found in the ASD +  ADHD 
group compared to the TD group, p = 0.90. In addition, when 
comparing the immunological profiles of the ASD-only and 
ASD + ADHD group, the ASD + ADHD group demonstrated 
significantly higher MIF, p = 0.03, and lower CXCL8, p = 0.01, 
concentrations than did the ASD-only group. Nevertheless, it 
is noted that a significantly lower concentration of CXCL9 was 
observed in both the ASD-only, p < 0.001, and ASD + ADHD 
groups, p =  0.006, compared with the TD controls. Moreover, 
a trend of elevated CCL5 was observed in both the ASD-only, 
p = 0.10, and ASD + ADHD groups, p = 0.07, when compared 
to the concentrations measured for the TD controls, suggesting a 
small degree of similarity between the immunological profiles of 
the ASD-only and ASD + ADHD groups.
DiscUssiOn
The present study examined cognitive function deficits and 
behavioral problems among a group of children with ASD who 
were aged 6–17 years and whether these deficits were associated 
with altered pro-inflammatory cytokine and chemokine profiles. 
The findings of the present study showed deviated concentrations 
of serum cytokines and chemokines, with elevated macrophage/
monocytes CCL2 and levels of the Th2-related chemokine CCL5 
and reduced levels of the T helper type 1 (Th1)-related chemokine 
CXCL9 in children with ASD compared to TD controls. 
Consistent results were obtained from the subgroup analyses 
involving only male participants from each group and after con-
trolling for age differences, suggesting that neither gender nor 
age could account for differences in the immunological profiles 
between the two groups of children. In addition, the deviations in 
CCL5 and CXCL9 were linked to impairments in the behavioral 
domains, with associations observed between more behavioral 
problems measured in the three behavioral domains, including 
social communication/interaction, repetitive/restricted behavior, 
and inattention/hyperactivity, and increased levels of CCL5 and 
decreased CXCL9, such that impairments in the behavioral 
domains were more pronounced in individuals with deviations in 
the concentrations of these two chemokines. The present results 
are in line with those of previous studies showing an increase in 
plasma levels of CCL2 and CCL5 in individuals with ASD (1, 8). 
In what appears to be an important extension of previous studies, 
our findings are the first to show significantly reduced concentra-
tions of CXCL9 in children with ASD compared to TD controls. 
The reduced levels of CXCL9 may be related to the slight decrease 
in the levels of the Th1-related chemokine CXCL10 in the ASD 
and ASD +  ADHD groups, given that CXCL9 is a chemokine 
that is structurally and functionally related to CXCL10, which 
binds to a common inflammatory chemokine receptor, CXCR3, 
to coordinate inflammation in a variety of human diseases (9, 33). 
In fact, a positive correlation was found between levels of CXCL9 
and CXCL10 in the present study, r = 0.35, p = 0.04, indicating that 
both of these chemokines may have important implications in the 
inflammatory mechanism in ASD, in that their levels of produc-
tion show similar patterns. This finding may provide additional 
evidence of the involvement of CXCL9 in the pathophysiology 
of ASD for future research, given that CXCL9 has been relatively 
unexplored in previous studies. Furthermore, considering dif-
ferent cytokines/chemokines can be secreted by different T cell 
subsets, such as Th1, Th2, Th17, Th22, Th9, regulatory T cells, 
and follicular T helper cells; or leukocytes subsets including mac-
rophages, dendritic cells, neutrophils, natural killers, and natural 
killer cells, it is reasonable to postulate that different cell number 
of the T cell subsets and leukocytes presented in ASD and the TD 
controls are responsible for the observed differences in cytokine/
chemokine levels between the two groups of children.
However, in contrast to previous findings that have repeat-
edly indicated a significant reduction in TGFβ1 and a role for 
this reduction in the neuroinflammatory process of ASD (1, 4, 
8–10), our results showed no difference in TGFβ1 between the 
TD and ASD groups. One possible reason could be related to the 
uniqueness of the genetic and environmental characteristics of 
different ethnic groups, varying immunological measures such 
as white blood cell counts and percentages of lymphocytes and 
granulocytes have been found to vary among different races (34, 
35). For example, the association between decreased circulating 
concentrations of TGFβ1 and the severity of behavioral symptoms 
in ASD has been consistently reported in studies on Caucasians. 
In contrast, a study conducted on Japanese individuals with ASD 
did not demonstrate such an association between decreased 
serum levels of TGFβ1 and ASD symptoms (10). Another possible 
reason is the different biological samples analyzed. In most previ-
ous studies on peripheral levels of MIF and TGFβ1, samples were 
collected from plasma, whereas the samples used in the present 
study were collected from serum. It is still unknown whether the 
plasma level of cytokines directly reflects the serum level of the 
same cytokines (8, 10, 36–40). Nevertheless, given the relatively 
small sample size in the present study, further verification with a 
larger sample size is necessary before any firm conclusions can 
be drawn.
Furthermore, autism is a broad spectrum of disorders over 
which affected individuals demonstrate a broad range of symptoms 
in social and behavioral respects, with approximately 30–50% of 
ASD individuals showing prominent ADHD symptoms (15), 
and ASD children with or without ADHD have been found to 
exhibit distinct cognitive and behavioral profiles (15–19). For 
this reason, the present study also aimed to explore whether 
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different immune mechanisms are active in these children. 
Interestingly, findings from the present study have demonstrated 
a robustly increased level of CCL2 in the ASD group but not in 
the ASD  +  ADHD group. Specifically, robust between-group 
differences were observed in the elevated concentration of CCL2 
between our samples of ASD-only and TD controls. On one hand, 
these results agree with the majority of findings reported in the 
literature indicating that substantially higher concentrations of 
CCL2 are observed across different biological samples, includ-
ing plasma, CSF, astrocytes in the anterior cingulate gyrus, and 
even tissue from the cerebellum, where elevated concentrations 
of CCL2 appear to be relatively stable across a broad age range 
(from newborn to middle-aged adults) and across various levels 
of intellectual functioning (with or without mental disabilities) 
among individuals with ASD (1, 6, 7, 14). Given the critical role 
of CCL2 in the proinflammatory process and its implication in 
neuroinflammation underlying the pathogenesis of certain CNS 
diseases, e.g., Alzheimer’s disease (41–45), it is postulated that the 
elevated CCL2 levels observed in the present study may indicate 
neuroinflammation in ASD. However, it should be noted that, 
in contrast to previous studies that showed associations between 
increased CCL2 and impairments in behavioral functions among 
individuals with ASD (6), the lack of between-group differences 
for the ASD + ADHD group and the absence of a significant asso-
ciation of CCL2 with any of the cognitive or behavioral measures 
considered in the present study warrants future work to delineate 
the role of CCL2 in the expression of autistic traits.
It is worth noting that although a non-significant trend of 
increased MIF and decreased CXCL10 was observed in children 
with ASD, significant associations were in fact detected between 
these deviations and poorer performance in the EF domain. 
Specifically, an increased MIF but reduced levels of the Th1-
related chemokine CXCL10 were related to poorer executive 
performance. Furthermore, increased CXCL9 was associated 
with decreased short-term memory, and increased CCL5 was 
shown to be highly associated with more severe inattention/
hyperactivity problems. Moreover, it is interesting to see that 
elevated MIF and decreased CXCL8 levels were found only in 
children with ASD comorbid with ADHD but not in children of 
the ASD-only group. Although the mechanism underlying the 
distinctive immunological profile of ASD and ASD + ADHD is 
unknown, this study provides important information indicating 
a potentially distinct cytokine/chemokine profile between dif-
ferent subtypes of autistic disorder. This notion is in agreement 
with previous studies that reported the opposite pattern of CCL5 
concentrations between autistic individuals with and without 
FXS (14). In fact, our results seem to suggest that lumping ASD 
individuals with varying phenotypes into one group for analysis 
may in fact dilute the between-group difference relative to the 
control. Given the relaxed diagnostic criteria of the DSM-V that 
allows for the dual diagnosis of ASD and ADHD, it is worth 
further exploring the immunological difference between indi-
viduals with ASD-only and those with a co-diagnosis of ADHD 
in future studies. For example, it will be of interest to investigate 
the functional role of CCL5 in individuals with ADHD and to 
examine further whether CCR5 blockers will improve attention 
in animal models of ASD.
Although interesting associations that suggest the role of 
inflammatory chemokines and cytokines in the pathogenesis of 
ASD were observed in the present study, it should be noted that our 
findings of the association between concentrations of cytokines 
and chemokines and behavioral functions in ASD were not as 
strong as we hypothesized. A significant association was detected 
only between increased levels of the Th2-related chemokine 
CCL5 and more inattention/hyperactivity problems, which is in 
contrast with previous studies reporting a significant association 
between increased levels of CCL5 and greater impairments in 
social and communication skills in individuals with ASD (6). 
Nevertheless, the extent of all associations found in the present 
study had a larger effect size compared to that of the significant 
correlations detected by Ashwood et al. (6). Additionally, regard-
ing the moderate degree of association between increased CXCL9 
levels and deficits in short-term memory, the finding is a novel one 
in the neuro-immunological field of research on ASD. Although 
the underlying mechanism of aberrant serum levels of CXCL9 on 
the pathogenesis of ASD is not known, given its close association 
with CXCL10, it may also play a role in coordinating the inflam-
matory process in ASD (33, 46). Further investigation is needed 
to determine the link between decreased CXCL9 levels and better 
short-term memory performance in ASD patients. Moreover, our 
finding of the significant association between decreased serum 
levels of CXCL10 and poorer executive performance in ASD is 
in contrast to previous studies that showed an increased plasma 
level of CXCL10 was positively associated with disease progres-
sion and mental flexibility and inhibitory control in patients with 
Parkinson’s disease (47). Thus, future research may be necessary 
to clarify whether the link between immunological abnormalities 
and cognitive functioning differ between diseases even if they 
both exhibit a neuroinflammatory profile.
Taken together, our results are in agreement with findings in 
previous studies showing that cytokines are involved in neurode-
velopment and neuronal function and that cytokine imbalance 
and dysregulation can have long term neurological consequences 
(48). Furthermore, the fact that cytokine expression is dependent 
on genetic and environmental influences (49) may help explain 
our findings that showed distinct immunological profiles in 
children with ASD of Chinese ethnicity from previous studies 
conducted in Western populations. Specifically, cytokines may 
represent a biomarker for genetic or environmental factors in 
autism. Of which, an individual may be genetically predisposed to 
mount an inappropriate immune response, either too robustly or 
too weakly, against an infectious or toxic substance which in turn 
could cause associated damage to the brain and other body sys-
tems, including the immune system, for the development of ASD. 
Moreover, an individual may lack appropriate genetic machinery 
to excrete and eliminate toxins; thereby causing their accumula-
tion in tissue or organ and subsequently lead to an amplification 
of the toxin’s effects in a variety of body systems, including the 
brain and the immune system. Therefore, certain environmental 
challenge during a critical period of child development could 
have especially severe consequences, causing abnormal CNS 
function, altered immune phenotypes, and autism. Although 
findings from the present study may implicate potential areas 
where manipulation targeting individual cytokine–receptor 
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interactions may impact on the behavior and immunity in ASD, 
whether this manipulation of the immune response represents a 
therapeutic strategy in the treatment of ASD remains uncertain. 
The reason being that cytokines/chemokines are a complex 
immune network and individuals with ASD of different ethnicity 
may have different genetic backgrounds and expose to different 
environmental factors, therefore therapeutic strategy targeting 
on one or two cytokines/chemokines may not be sufficient for 
providing a general treatment of ASD.
Overall, the present study provides preliminary findings 
regarding immunological dysfunction in the peripheral blood 
of children with ASD in a Chinese population. To the best of 
our knowledge, there are no previous studies such as this one 
in Chinese population and only few in other Asian cohorts. 
Moreover, what appears to be an important extension of 
previous studies is that in the present study, it was found that 
individuals with ASD that do and do not have ADHD symptoms 
exhibit distinct pro-inflammatory profiles; and that cognitive 
function deficits, repetitive stereotyped behavior and inatten-
tion/hyperactivity exacerbated as a function of altered plasma 
levels of chemokines and cytokines between the two different 
subtypes of autistic disorder. The findings from the present 
study bring together several diverse areas of research on autism 
and establish a link between immunological alteration and 
cognitive and behavioral impairments in autistic children with 
different ethnic backgrounds. However, the following should 
be noted when interpreting the data. One of the main limita-
tions of our study was the small sample size used, which may 
have led to the low statistical power detected in comparing the 
levels of chemokine and cytokine production between groups 
and the behavioral and cognitive correlations with the levels of 
chemokines and cytokines, although a moderate to large effect 
size was found. Moreover, a relatively weak relation between 
the concentrations of chemokines and cytokines and behavio-
ral performance was observed in our study, which was likely 
because the level of behavioral impairment in our sample was 
not as severe as expected but showed a narrow spread around 
the mean. Therefore, it was rather difficult to determine whether 
our observations reflect a true picture of the relationship 
between behavioral performance and immunological profiles 
in ASD among the general population. Further studies with a 
larger sample size will be required to verify the results before 
more conclusive interpretations can be made regarding the func-
tional role of cytokines play in ASD. In addition, the number of 
detected cytokines/chemokines in the plasma is relatively low in 
the present study, and it may be argued that the correlations of 
cytokines/chemokines in different tissues are highly dependent 
on the types of studied inflammatory cytokines/chemokines. 
For example, circulating plasma levels of cytokines may have 
certain correlation with the local concentrations inside the 
brain or CSF such as TNF-alpha in ASD. But IL-6 was found to 
be present in CSF but not in plasma in ASD (50). Furthermore, 
the expression of some cytokines, e.g., IL-1, IL-2, TGF-β, and 
granulocyte-macrophage colony-stimulating factor, is actually 
controversial, and different studies have found various results in 
different tissues. Further investigations are therefore required to 
elucidate the correlations of cytokines in different sites such as 
plasma and the brain.
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